# US 2021/0171564 A1 · Compositions and methods for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171564 A1
- Document ID: US20210171564A1
- Status: Published application
- Kind: A1
- Application number: 17/250,573
- Filed: 2019-07-09
- Published: 2021-06-10
- Earliest claimed: 2018-08-03
- Assignees: Cellix Bio Provate Limited
- Applicants: Cellix Bio Private Limited
- Inventors: Mahesh Kandula
- Web page: https://patentgrep.com/patent/US20210171564A1

## CPC

- C07H 19/06: Pyrimidine radicals
- A61P 35/00: Antineoplastic agents
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications.

## Claims

### Claim 1

A compound of Formula I:
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;
wherein
R1, R3, R5 independently represents NULL,
R2, R4 independently represent NULL, hydrogen,
R6 independently represents NULL,
within the proviso,
wherein
n represents 0 to 12;
R7 and R8 independently represents
with the proviso that when R2 and R4 is hydrogen then R6 is not

### Claim 2

A compound of Formula II:
and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof,
wherein
R1, R3, R5 independently represents NULL,
R2, R4 independently represent NULL, hydrogen,
R6 independently represents NULL,
wherein, n represents 0 to 12;
with the proviso that when R2 and R4 is hydrogen then R6 is not

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein said pharmaceutical composition is for oral administration, systemic administration, sustained release, parenteral administration, injection, dermal administration, drug-device, topical administration, subdermal administration, solution, syrup, or transdermal administration.

### Claim 5 (depends on 4)

The pharmaceutical compositions of claim 4, wherein said pharmaceutical composition is formulated for the treatment of cancer.

### Claim 6 (depends on 2)

A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein said pharmaceutical composition is for oral administration, systemic administration, sustained release, parenteral administration, injection, dermal administration, drug-device, topical administration, subdermal administration, solution, syrup, or transdermal administration.

### Claim 8 (depends on 7)

The pharmaceutical compositions of claim 7, wherein said pharmaceutical composition is formulated for the treatment of cancer.

### Claim 9

A compound selected from the group consisting of

### Claim 10 (depends on 9)

A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein said pharmaceutical composition is for oral administration, systemic administration, sustained release, parenteral administration, injection, dermal administration, drug-device, topical administration, subdermal administration, solution, syrup, or transdermal administration.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein said pharmaceutical composition is formulated for the treatment of cancer.
